Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.

Bioorganic chemistry - 1 Mar 2024

Shang Yanguo, Fu Shengnan, Hao Qingjing, Ying Hanjie, Wang Jinxin, Shen Tao

Abstract excerpt

KRAS is the most frequently mutated oncogene and drives the development and progression of malignancies, most notably non-small cell lung cancer (NSCLS), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). However, KRAS proteins have maintained the reputation of being "undruggable" due to the lack of suitable deep pockets on its surface. One major milestone for KRAS inhibition was the discovery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chemistry, Pharmaceutical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Development

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38271825
DOI: 10.1016/j.bioorg.2023.107092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.PMID 38271825Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Insights into direct KRAS inhibition strategies for cancer treatment.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.